NCT07822932 Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral Neuropathy
| NCT ID | NCT07822932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | HIV Associated Polyneuropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-11 |
| Primary Completion | 2028-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2026-11 with a primary completion date of 2028-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study looks at a non-invasive ear stimulation treatment to better understand nerve pain in people living with HIV. The study aims to assess how the body and nervous system respond to this treatment, including changes in heart function and pain signals. The goal is to learn how future treatments for nerve pain may be improved.
Eligibility Criteria
Inclusion Criteria: * Established HIV infection * Glove/stocking dysesthesias lasting for ≥3 months * HIV-associated peripheral neuropathy (HIV-PN) related symptoms ≥4 (on a scale of 0-10) within the last week * Stable medical care (i.e., no changes in Antiretroviral Therapy or pain medication within 2 months of enrollment) * Able to read the consent form, demonstrate understanding of study procedures and requirements, and independently provide written informed consent Exclusion Criteria: * Unstable cardiac disease * Implanted electronic or magnetic devices (e.g., pacemaker, cochlear implants, medication pumps, and other implanted neurostimulation systems) * Head or neck cancer or metastases * Recent ear trauma or metal implants in the head * History of epilepsy, unprovoked seizure, stroke, brain tumor, significant traumatic brain injury, prior intracranial surgery, or other neurological condition associated with increased seizure risk * Active or uncontrolled comorbidities that independently cause neuropathy (e.g., recent chemotherapy, uncontrolled diabetes with documented neuropathic complications) * Clinical evidence of non-HIV neuropathy (e.g., neuropathic symptoms predating HIV diagnosis, uncontrolled diabetes) * Known allergy to tape/adhesive * Ferromagnetic or non-MRI-compatible metal in the head, neck, eye, or cranial region, including aneurysm clips, retained metal fragments, bullets, shrapnel, or other metallic implants not demonstrated to be TMS-compatible. * Pregnancy or actively breast feeding
Contact & Investigator
Marlon L. Wong, PT, PhD
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT07822932 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying HIV Associated Polyneuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07822932 currently recruiting?
Yes, NCT07822932 is actively recruiting participants. Contact the research team at mwong2@miami.edu for enrollment information.
Where is the NCT07822932 trial being conducted?
This trial is being conducted at Miami, United States.
Who is sponsoring the NCT07822932 clinical trial?
NCT07822932 is sponsored by University of Miami. The principal investigator is Marlon L. Wong, PT, PhD at University of Miami. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.